 BeyondSpring Inc. the Company or BeyondSpring BYSI, a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that the Company will report its fourth-quarter and full-year 2019 financial results and host an operational update conference call on Thursday, April 30, 2020, at 8 a.m. Eastern Time. BeyondSpring is a global clinical-stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies. BeyondSpring has strong RD; capabilities with a robust pipeline in addition to Plinabulin, including three immuno-oncology assets and a drug discovery platform using the ubiquitination degradation pathway. 